CN103655589A - Pharmaceutical composition and preparation and usage thereof - Google Patents
Pharmaceutical composition and preparation and usage thereof Download PDFInfo
- Publication number
- CN103655589A CN103655589A CN201210327805.8A CN201210327805A CN103655589A CN 103655589 A CN103655589 A CN 103655589A CN 201210327805 A CN201210327805 A CN 201210327805A CN 103655589 A CN103655589 A CN 103655589A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- gentiopicrin
- preparation
- composition described
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the field of medical technology and discloses a pharmaceutical composition and a preparation and a usage thereof, wherein the pharmaceutical composition contains gentiopicrin and loganin acid; the pharmaceutical composition is determined by scientific experiments. The experiments have proven that the loganin acid generates no effect on the stability of the gentiopicrin, and pharmacological experiments have proven that the loganin acid and the gentiopicrin have a synergistic effect.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of pharmaceutical composition that contains gentiopicrin active component and preparation and purposes.
Background technology
Liver is that to take metabolic function in health be a main organ, and in health the inside, is playing the part of deoxidation, stores the effect such as synthetic of glycogen, secreted protein.Liver is the organ that body weight for humans is wanted, and wherein hepatitis is commonly encountered diseases, frequently-occurring disease, and its type mainly contains three: one, viral hepatitis, the 2nd, alcoholic hepatitis, the 3rd, drug induced hepatitis.The traditional Chinese medical science is referred to as jaundice.Modal in clinical is viral hepatitis.The hepatitis acute attack stage traditional Chinese medical science is often called " YANG jaundice ", and acute hepatitis transfers chronic hepatitis to or the PCH traditional Chinese medical science is called " YIN jaundice ".Hepatitis virus carrier accounts for total crowd's 46%, and sickness rate is 15%, that is to say that it is hepatitis patients that approximately there are 200,000,000 people in the whole nation.China is that whole world hepatitis endangers maximum country, and sickness rate ranks first in the world.Having a strong impact on the healthy of people, is the significant problem that must cause that colleague pays close attention to.Just because of above-mentioned reason, countries in the world, each large pharmacy corporation are all in the searching for the treatment of hepatitis medicine of throwing oneself into.China is except schizandrol, bifendate, zinc glycyrrhetate, silibinin single or single component, and Chinese medicine compound is lower hundreds of, in the symptom of hepatitis alleviates and treats, has played positive role.But the healing degree to hepatitis is far from satisfactory.These medicines are mostly oral formulations, and injection is less, all exist treatment cycle long, control the imprecise drawback of effect.
Gentiopicrin forms from the medicinal material extract such as Radix Gentianae Macrophyllae are refining, and relevant gentiopicrin pharmacodynamics aspect research is both at home and abroad more, is mainly hepatic cholagogic aspect report, and pharmacological toxicology and clinical experimental study show that gentiopicrin is safe and effective.Gentiopicrin can increase bile cholesterol and bilirubinic excretion, can improve Na
+, K
+the activity of-ATP enzyme.Can obviously reduce ALT, AST and LDH, to hepatic tissue pathology, damage has certain improvement effect.Gentiopicrin also can suppress the generation of TNF in serum, shows that gentiopicrin is by suppressing TNF, and suppresses hepatitis.
Therefore, take gentiopicrin as material base, carry out deep exploitation, will there is deep scientific meaning.
Summary of the invention
For these reasons, applicant, by the test of science, determines and take gentiopicrin as basis, finds a kind of new pharmaceutical composition, and this pharmaceutical composition comprises gentiopicrin and lognic acid; Stability test shows, lognic acid for gentiopicrin stability without any impact; Pharmacodynamics test shows, this pharmaceutical composition has collaborative pharmacological action.
The present invention realizes by following proposal.
A pharmaceutical composition, pharmaceutical composition comprises gentiopicrin and lognic acid.
A pharmaceutical composition, wherein gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and lognic acid weight content is greater than 0 and be less than or equal to 10%.
A pharmaceutical composition, wherein gentiopicrin weight content is for being more than or equal to 96% and be less than 100%, and lognic acid weight content is greater than 0 and be less than or equal to 5%.
A pharmaceutical composition, wherein gentiopicrin weight content is for being more than or equal to 98% and be less than 100%, and lognic acid weight content is greater than 0.1 and be less than or equal to 1%.
Pharmaceutical composition described above is the pharmaceutical preparation that raw material is prepared into.
Preparation described above comprises oral formulations.
Preparation described above comprises ejection preparation.
Pharmaceutical composition described above application in preparing hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
Pharmaceutical composition described above application in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Oral formulations described above comprises tablet or capsule.
Ejection preparation described above comprises lyophilized injectable powder.
Pharmaceutical composition of the present invention includes but not limited to that extraction obtains the effective ingredient that contains gentiopicrin and lognic acid from the plants such as Radix Gentianae Macrophyllae; Concrete preparation method, can adopt methods such as preparing liquid phase process or column chromatography.
One, stability test
1, trial drug:
Test 1 group: gentiopicrin.
Test 2 groups: lognic acid.
Test 3 groups: gentiopicrin 9.5g, lognic acid 0.5g, mix homogeneously, standby.
2, test method:
(1) exposure experiments to light: get different tests sample, loose dividing in little culture dish, the about 5mm of thickness.Be placed on the proof box of medicine strong illumination (SHH-100GD, Chongqing immortality experimental apparatus factory; LHH-250GP, upper sea blue leopard testing equipment company limited), under illumination 4500Lx ± 500Lx condition, to place 10 days, sampling in the 10th day, detects, and result is compared with 0 month data.Result of the test is in Table 1.
(2) hot test: sample thief, is placed in small beaker, diaphragm seal sealing.Be placed on electric drying oven with forced convection (DHG-9023A, Shanghai Yi Heng Science and Technology Ltd.), under 60 ℃ ± 1 ℃ condition, place 10 days, sampling in 10 days detects, and result is compared with 0 month data.Result of the test is in Table 2.
(3) high wet test: sample thief, be placed in small beaker, be placed in respectively and fill NaCl saturated solution and KNO
3the close drying device of saturated solution, damp condition is respectively RH75%.It is placed in respectively to electric drying oven with forced convection (DHG-9023A, Shanghai Yi Heng Science and Technology Ltd.), under 25 ℃ ± 1 ℃ condition, places 10 days, sampling in the 10th day detects, and result is compared with 0 month data.Result of the test is in Table 3.
3, detection method:
(1) gentiopicrin detection method
According to high performance liquid chromatography (appendix VI D of < < Chinese Pharmacopoeia > > version in 2010), measure.
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; The methanol-water (3: 7) of take is mobile phase; Detection wavelength is 270nm.Number of theoretical plate is pressed gentiopicrin peak and is calculated, and should be not less than 3000.
It is appropriate that the preparation precision of reference substance solution takes gentiopicrin reference substance, adds mobile phase and make every 1ml containing the solution of 0.5mg, obtains.
It is appropriate that the preparation precision of need testing solution takes this product, adds mobile phase and make every 1ml containing the solution of 0.5mg, obtains.
Algoscopy is accurate reference substance solution and each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
(2) lognic acid detection method
According to high performance liquid chromatography (appendix VI D of < < Chinese Pharmacopoeia > > version in 2010), measure.
Chromatographic condition and system suitability experiment are filler with octadecylsilane chemically bonded silica; Methanol-0.5% acetic acid the water (25: 75) of take is mobile phase; Detection wavelength is 238nm.
It is appropriate that the preparation precision of reference substance solution takes lognic acid reference substance, adds mobile phase and make every 1ml containing the solution of 0.5mg, obtains.
It is appropriate that the preparation precision of need testing solution takes this product, adds mobile phase and make every 1ml containing the solution of 0.5mg, obtains.
Algoscopy is accurate reference substance solution and each 10 μ l of need testing solution of drawing respectively, and injection liquid chromatography, measures, and obtains.
4, testing result:
Table 1 exposure experiments to light result
Table 2 hot test result
Table 3 high humidity result of the test
Conclusion (of pressure testing): aforementioned stable test shows, gentiopicrin and lognic acid are carried out to compatibility, high temperature, high humidity, high light do not affect for the two content, illustrate gentiopicrin and lognic acid the two aspect stability without interaction.
Two, pharmacological test example
Embodiment 1
Protective effect to isolated liver cell apoptosis
Experimental animal: Kunming mouse, male, 4 week age.
Trial drug:
1 group of trial drug: gentiopicrin 30mg/kg.
2 groups of trial drugs: lognic acid 30mg/kg.
3 groups of trial drugs: gentiopicrin 27mg/kg, lognic acid 3mg/kg.
4 groups of trial drugs: gentiopicrin 27.4mg/kg, lognic acid 2.6mg/kg.
Test reagent: formaldehyde; CoulterDNA-PrepReagentsKit test kit (DNA-PrepLPR fixative, DNA-Prepstain dyestuff).
Test apparatus: autobalance micro centrifuge; Flow cytometer.
Test method: by mice random packet: Normal group, model group, trial drug group.Administration group tail vein injection every day gives relative medicine, dosage 30mg/kg, and Normal group, model group tail vein injection every day such as give at the capacity normal saline, continuous 7d, fasting (freely drinking water) 12h before administration in the 7th day, after administration 2h, de-cervical vertebra is put to death animal.Respectively get 2mm * 2mm * 1mm left and right fritter leftlobe of liver tissue, add 5ml normal saline, on 200 mesh filter screens, grind, and constantly filter, blow and beat into unicellular, the centrifugal 5min of 4000r/min, abandoning supernatant, residual liquid shakes even, get 10 μ l Cell saps, Normal group adds 5mlNS, all the other each groups respectively add 5ml1% formaldehyde, 2～4 ℃ of cold preservation 15min, the centrifugal 5min of 4000r/min, abandoning supernatant, residual liquid adds respectively 5ml normal saline and cleans, centrifugal, remove supernatant, each Guan Jun washes 2 times, abandoning supernatant, residual liquid adds 50 μ lDNA-PrepLPR fixatives, vibration, add 450 μ lDNA-Prepstain dyestuffs, lucifuge 30min, with flow cytometer, detect.
Result of the test: the results are shown in Table 4.
Table 4 is on respectively organizing the impact of isolated liver cell cycle and apoptosis
Note: compare * * P < 0.01 with model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 2
To CCl
4cause the protective effect of acute liver
Experimental animal: KM mice, rank: healthy secondary, the age: 6.5 ± 0.5 weeks, sex: male and female half and half, body weight: 20 ± 2g.
Trial drug:
1 group of trial drug: gentiopicrin 30mg/kg.
2 groups of trial drugs: lognic acid 30mg/kg.
3 groups of trial drugs: gentiopicrin 29mg/kg, lognic acid 1mg/kg.
4 groups of trial drugs: gentiopicrin 29.4mg/kg, lognic acid 0.6mg/kg.
Test reagent: CCl
4; Olive oil.
Test method: mice is pressed to body weight random packet: blank group, model group, trial drug 1-4 group, male and female half and half.Each administration group is pressed trial drug group tail intravenously administrable, and blank group and model group give isopyknic distilled water, every day 1 time, continuous 7 days.20:00 removed food on 1, and after 8:00 weighed on 1, once, 16:00 abdominal cavity gives 0.1%CCl to tail intravenously administrable
410ml/kg, blank group gives isopyknic olive oil with method, within 8th, weighs and gets fasting blood, and separation of serum, measures and respectively organizes Serum ALT and AST.
Result of the test: the results are shown in Table 5.
Table 5 couple CCl
4cause acute liver impact
Note: compare * * P < 0.01 with model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 3
Protective effect to rat chronic hepatic injury
Experimental animal: Wistar rat, male, body weight: 200 ± 2g.
Trial drug:
1 group of trial drug: gentiopicrin 20mg/kg.
2 groups of trial drugs: lognic acid 20mg/kg.
3 groups of trial drugs: gentiopicrin 19mg/kg, lognic acid 1mg/kg.
4 groups of trial drugs: gentiopicrin 19.3mg/kg, lognic acid 0.7mg/kg.
Test reagent: CCl
4; Olive oil.
Test method: rat is pressed to body weight random packet: normal group, model group, trial drug group.Except blank group, other respectively organize subcutaneous injection 40%CCl
4olive oil solution 5ml/kg, later subcutaneous injection 40%CCl weekly
4olive oil solution 3ml/kg twice, continues 6 weeks, blank group of olive oil that gives same volume.Simultaneously all the other each groups are according to identical pharmaceutical quantities tail every day intravenously administrable 1 time, and successive administration 6 weeks, weighs weekly once, according to the variation of body weight, adjusts dosage.After last administration 24 hours, get the blood sample of animal, separation of serum is measured respectively ALT, AST, TP and Alb by automatic clinical chemistry analyzer.The animal of drug withdrawal time daily femoral artery sacrificed by exsanguination, is cooked substantially and histopathologic examination.Measure weight and the coefficient of liver, spleen; Take out each treated animal liver, the conventional dehydration of leftlobe of liver, embedding and section, histological examination is done in HE dyeing.
Result of the test: the results are shown in Table 6, table 7.
The impact of table 6 different pharmaceutical on rat liver coefficient
Note: compare * * P < 0.01, * P < 0.05 with model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
The impact of table 7 on rat blood biochemical indicator and Liver hydroxyproline content
Note: compare * * P < 0.01, * P < 0.05 with model group; Compare #P < 0.05 with 1 group of test; Compare %P < 0.05 with 2 groups of tests.
Embodiment 4
Impact on rat bile secretion
Experimental animal: Wistar rat, rank: healthy secondary, the age: 7 ± 0.5 months, sex: male, body weight: 310 ± 30g.
Trial drug:
1 group of trial drug: gentiopicrin 20mg/kg.
2 groups of trial drugs: lognic acid 20mg/kg.
3 groups of trial drugs: gentiopicrin 19.5mg/kg, lognic acid 0.5mg/kg.
4 groups of trial drugs: gentiopicrin 19.3mg/kg, lognic acid 0.7mg/kg.
Test reagent: urethanes (urethane); Sodium chloride injection.
Test apparatus: electronic balance; Air dry oven; The portable sterilizer of coal and electricity dual-purpose.
Test method: rat fasting be can't help water 12 hours, lumbar injection 20% urethane solution (5ml/kg) anesthesia, face upward position fixing, routine disinfection, along ventrimeson, cutting the otch of 2cm, open abdominal cavity, in descendant duodenum mesentery, find the bile duct of white flexible, separated bile duct, will, near the firm ligation in duodenal one end, do a v-notch with eye scissors to liver direction from the nearly duodenum seam of bile duct, capillary plastic tube is inserted in common bile duct, visible have pistac bile to flow out, and ligation fixed plastics pipe, collects bile with small beaker.
Rat is divided into blank group at random by body weight, trial drug group.Used after operation hemostasis clamp closes abdominal cavity, with saline gauze, cover, after stablizing 20min, first collect 30min bile, then respectively organize rat tail vein administration, blank group gives distilled water, trial drug group dosage is 20mg/kg, and after administration, every 30min measures bile once, totally 4 times, the bile volume before and after rat administration respectively organized in record, bile secretion percentage rate after calculating administration.
Result of the test: the results are shown in Table 8.
The impact of table 8 on rat bile flow
Note: compare * * P < 0.01, * P < 0.05 with model group; Compare #P < 0.05 with 1 group of test and compare %P < 0.05 with 2 groups of tests.
Embodiment 5
Hepatitis virus resisting effect
Experimental animal: Beijing duck.
Trial drug:
1 group of trial drug: gentiopicrin 208.8mg/kg, lognic acid 1.2mg/kg.
4 groups of trial drugs: gentiopicrin 207.9mg/kg, lognic acid 1.1mg/kg, magnesium isoglycyrrhetate 1mg.
Test reagent: DHBV-DNA is positive, and Sanguis Anas domestica is clear.
Test apparatus: probe.
Test method: get Beijing duck, clear through the positive Sanguis Anas domestica of lower limb shin intravenous injection DHBV-DNA, every 0.3ml, infects and get blood in latter 7 days, and separation of serum detects DHBV-DNA content in serum.Sanguis Anas domestica after DHBV is positive clearly after testing, is divided into group at random by duck: virus control group, trial drug group, and each is organized lumbar injection and gives medicine, every day 2 times, dosage 210mg/kg, matched group gives same volume normal saline, successive administration 10 days.Respectively with Drug therapy after after 5 days (T5), 10 days (T10) and drug withdrawal 3 days (P3) from duck shin venous blood sampling, separation of serum, press nick translation test kit description method, with 32P labelling DHBV-DNA probe, and make the clear dot blot hybridization of Sanguis Anas domestica, and autoradiography diaphragm speckle, microplate reader is measured OD value (optical filter is 490nm), calculate serum DHBV-DNA optical density, using hybridization spot OD value as specimen DHBV-DNA level value.
Result of the test: the results are shown in Table 9.
Table 9 is the impact on DHV DHBV-DNA in duck body
Note: compare * * P < 0.01 with T0 group.
Two, toxicology test example
Test example 1
Acute toxicity test to mice
Experimental animal: ICR Strains of Mouse, 18-22g.
Trial drug:
Test 1 group: gentiopicrin.
Test 2 groups: gentiopicrin 0.85g, lognic acid 0.15g.
Test 3 groups: gentiopicrin 0.90g, lognic acid 0.10g.
Test 4 groups: gentiopicrin 0.95g, lognic acid 0.05g.
Test method: get ICR mice, before experiment, the about 15h of water is can't help in fasting, is divided into 25 groups (6 groups of every trial drug groups, 1 group of matched group).Each organizes mouse tail vein administration, test 1 group and be all according to dosage respectively 300mg/kg, 450mg/kg, 900mg/kg, 1500mg/kg, 2100mg/kg, 2700mg/kg (be equivalent to respectively intend quantity 10,15,30,50,70,90 times) to testing 4 groups of dosages, control group mice gives same volume distilled water.Examine and record toxic reaction and death condition that administration occurs to mice in 7d at once; Adopt Bliss ' s method to calculate LD50.
Result of the test: in Table 10.
The LD50 comparison of table 10 different tests group medicine
| Group | mg/kg |
| Test 1 group | 2809.94±193.394 |
| Test 2 groups | 1437.63±88.756 |
| Test 3 groups | 2012.41±94.452 |
| Test 4 groups | 2107.54±132.45 |
Conclusion (of pressure testing): above-mentioned acute toxicity test shows, medicine (gentiopicrin) LD50 that does not contain lognic acid surpasses 2000mg/kg, and along with the content of lognic acid in compositions increases, its LD50 is more and more less, therefore, in preferred composition, lognic acid content is no more than 10%.
Sum up: above-mentioned pharmacodynamics test and toxicology test show, in preferred pharmaceutical composition of the present invention, gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and lognic acid weight content is greater than 0 and be less than or equal to 10%.
Preparation Example
Embodiment 1
A pharmaceutical composition, gentiopicrin 72g in pharmaceutical composition, lognic acid 8g; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 2
A pharmaceutical composition, gentiopicrin 76g in pharmaceutical composition, lognic acid 4g; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 3
A pharmaceutical composition, gentiopicrin 79.2g in pharmaceutical composition, lognic acid 0.8g; Add mannitol 90g; Be prepared into 1000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 4
A pharmaceutical composition, gentiopicrin 316.8g in pharmaceutical composition, lognic acid 3.2g; Add lactose 2150g, low-substituted hydroxypropyl cellulose 113g, magnesium stearate 10g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 5
A pharmaceutical composition, gentiopicrin 398g in pharmaceutical composition, lognic acid 2g; Add lactose 2146g, low-substituted hydroxypropyl cellulose 112g, magnesium stearate 11g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 6
A pharmaceutical composition, gentiopicrin 364g in pharmaceutical composition, lognic acid 36g; Add lactose 2146g, low-substituted hydroxypropyl cellulose 115g, magnesium stearate 13g, is prepared into 5000, tablet.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 7
A pharmaceutical composition, gentiopicrin 316.8g in pharmaceutical composition, lognic acid 3.2g, is prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 8
A pharmaceutical composition, gentiopicrin 398g in pharmaceutical composition, lognic acid 2g; Be prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 9
A pharmaceutical composition, gentiopicrin 364g in pharmaceutical composition, lognic acid 36g; Be prepared into 5000 of aqueous injection.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 10
A pharmaceutical composition, gentiopicrin 364g in pharmaceutical composition, lognic acid 30g, kurarinone 2g, adds mannitol 465g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 11
A pharmaceutical composition, gentiopicrin 372g in pharmaceutical composition, lognic acid 20g, kurarinone 8g, adds mannitol 452g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Embodiment 12
A pharmaceutical composition, gentiopicrin 396g in pharmaceutical composition, lognic acid 3g, kurarinone 1g, adds mannitol 446g, is prepared into 5000 of lyophilized injectable powders.
This pharmaceutical composition is for the application at preparation treatment hepatic.
Pharmaceutical composition described above application in preparing function of gallbladder promoting medicine.
The application of aforementioned pharmaceutical compositions in preparation antiviral drugs.
Pharmaceutical composition described above application in preparation treatment hepatitis B medicine.
Pharmaceutical composition described above application in preparing Hepatoma therapy medicine.
Described embodiment includes but not limited to above-mentioned.
Claims (14)
1. a pharmaceutical composition, is characterized in that pharmaceutical composition comprises gentiopicrin and lognic acid.
2. a kind of pharmaceutical composition according to claim 1, wherein gentiopicrin weight content is for being more than or equal to 90% and be less than 100%, and lognic acid weight content is greater than 0 and be less than or equal to 10%.
3. a kind of pharmaceutical composition according to claim 1, wherein gentiopicrin weight content is for being more than or equal to 96% and be less than 100%, and lognic acid weight content is greater than 0 and be less than or equal to 5%.
4. a kind of pharmaceutical composition according to claim 1, wherein gentiopicrin weight content is for being more than or equal to 98% and be less than 100%, and lognic acid weight content is greater than 0.1 and be less than or equal to 1%.
5. according to a kind of pharmaceutical composition described in claim 1-4 any one, be the pharmaceutical preparation that raw material is prepared into.
6. pharmaceutical preparation according to claim 5, wherein preparation comprises oral formulations.
7. pharmaceutical preparation according to claim 5, wherein preparation comprises ejection preparation.
8. the application in preparing hepatic according to a kind of pharmaceutical composition described in claim 1-4 any one.
9. the application in preparing function of gallbladder promoting medicine according to the pharmaceutical composition described in claim 1-4 any one.
10. the application in preparation antiviral drugs according to the pharmaceutical composition described in claim 1-4 any one.
11. application in preparation treatment hepatitis B medicine according to the pharmaceutical composition described in claim 1-4 any one.
12. application in preparing Hepatoma therapy medicine according to the pharmaceutical composition described in claim 1-4 any one.
13. pharmaceutical preparatioies according to claim 6, wherein oral formulations comprises tablet or capsule.
14. pharmaceutical preparatioies according to claim 7, wherein ejection preparation comprises lyophilized injectable powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210327805.8A CN103655589A (en) | 2012-09-07 | 2012-09-07 | Pharmaceutical composition and preparation and usage thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210327805.8A CN103655589A (en) | 2012-09-07 | 2012-09-07 | Pharmaceutical composition and preparation and usage thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103655589A true CN103655589A (en) | 2014-03-26 |
Family
ID=50295151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210327805.8A Pending CN103655589A (en) | 2012-09-07 | 2012-09-07 | Pharmaceutical composition and preparation and usage thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655589A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1590398A (en) * | 2004-05-28 | 2005-03-09 | 胡少勇 | Preparation of gentian effective part and its application |
| CN1660124A (en) * | 2004-12-27 | 2005-08-31 | 孙文基 | Application of gentiopicrin in preparing medication for restraining hepatitis B virus |
-
2012
- 2012-09-07 CN CN201210327805.8A patent/CN103655589A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1590398A (en) * | 2004-05-28 | 2005-03-09 | 胡少勇 | Preparation of gentian effective part and its application |
| CN1660124A (en) * | 2004-12-27 | 2005-08-31 | 孙文基 | Application of gentiopicrin in preparing medication for restraining hepatitis B virus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104510747B (en) | A kind of new medicine use of iridoid glycoside | |
| Sun et al. | Effects and mechanisms of extract from Paeonia lactiflora and Astragalus membranaceus on liver fibrosis induced by carbon tetrachloride in rats | |
| CN101721488B (en) | Pharmaceutical composition for treating liver diseases and prepration method thereof | |
| CN103655590A (en) | Pharmaceutical composition containing gentiopicroside and preparation and usage thereof | |
| CN101669979A (en) | Artemisia scoparia extractive and production method and applications thereof | |
| CN101002849B (en) | Traditional Chinese medicine extractive or tablet for treating hepatitis, and its preparing method | |
| CN103845354A (en) | Pharmaceutical composition containing gentiopicroside and its preparation and use | |
| KR19990015612A (en) | Hepatitis C Therapeutic Composition Containing Mixed Extracts of Hwangbaekpi and Matari Plants | |
| CN107383150B (en) | A kind of compound and its preparation method and application with antihepatitis activity | |
| CN101134040B (en) | Application of forsythiaside in the preparation of medicament for treating or preventing acute and chronic liver damnification and liver fibrosis | |
| CN102532229B (en) | Pregnane glycoside compounds with orthoester groups and applications thereof | |
| CN103655589A (en) | Pharmaceutical composition and preparation and usage thereof | |
| CN103655591A (en) | Medicinal composition as well as preparation and application thereof | |
| CN108514568A (en) | The preparation method and its medical usage of thiazides compounds in the achene of Siberian cocklebur | |
| CN100584345C (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, extraction method and application | |
| CN102940621B (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis | |
| CN103610798B (en) | Active site of a kind of Herba Hedyotidis Diffusae and preparation method thereof, application | |
| CN101829086B (en) | Application of aromatic carbamoyl dehydro-silibinin as medicament for treating viral hepatitis B | |
| CN1969937B (en) | Pharmaceutical composition for treating hepatitis | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN103055006A (en) | Effective part of Houttuynia cordata as well as extracting method and application thereof | |
| CN109568419A (en) | A kind of Morinda officinalis total iridoid glycoside and its preparation method and application | |
| CN110840969B (en) | Traditional Chinese medicine composition for treating hepatitis C and application thereof | |
| CN1985988B (en) | Novel medicine composition for treating hepatic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140326 |